Free Trial

XOMA Royalty (XOMA) Competitors

XOMA Royalty logo
$27.71 +1.25 (+4.72%)
As of 04:00 PM Eastern

XOMA vs. XOMAO, DVAX, INVA, NVAX, MNKD, OPK, GERN, RGLS, MYGN, and ZBIO

Should you be buying XOMA Royalty stock or one of its competitors? The main competitors of XOMA Royalty include XOMA (XOMAO), Dynavax Technologies (DVAX), Innoviva (INVA), Novavax (NVAX), MannKind (MNKD), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), and Zenas BioPharma (ZBIO). These companies are all part of the "medical" sector.

XOMA Royalty vs. Its Competitors

XOMA (NASDAQ:XOMAO) and XOMA Royalty (NASDAQ:XOMA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

95.9% of XOMA Royalty shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, XOMA Royalty's average media sentiment score of 0.74 beat XOMA's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the news media.

Company Overall Sentiment
XOMA Neutral
XOMA Royalty Positive

XOMA has higher earnings, but lower revenue than XOMA Royalty.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA$13.05MN/AN/AN/AN/A
XOMA Royalty$28.49M11.64-$13.82M-$1.15-24.10

XOMA Royalty has a consensus target price of $69.50, indicating a potential upside of 150.81%. Given XOMA Royalty's stronger consensus rating and higher probable upside, analysts plainly believe XOMA Royalty is more favorable than XOMA.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XOMA
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
XOMA Royalty
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

XOMA has a net margin of 0.00% compared to XOMA Royalty's net margin of -13.04%. XOMA's return on equity of 0.00% beat XOMA Royalty's return on equity.

Company Net Margins Return on Equity Return on Assets
XOMAN/A N/A N/A
XOMA Royalty -13.04%-12.43%-4.85%

Summary

XOMA Royalty beats XOMA on 7 of the 10 factors compared between the two stocks.

Get XOMA Royalty News Delivered to You Automatically

Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XOMA vs. The Competition

MetricXOMA RoyaltyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$316.64M$2.90B$5.51B$8.96B
Dividend YieldN/A2.44%5.25%4.02%
P/E Ratio-24.1021.0128.0520.15
Price / Sales11.64294.68438.14127.85
Price / CashN/A41.8337.0657.97
Price / Book3.997.868.125.62
Net Income-$13.82M-$54.95M$3.16B$248.50M
7 Day Performance6.13%6.24%4.40%5.54%
1 Month Performance9.61%5.70%4.09%7.52%
1 Year Performance12.83%8.08%34.53%22.06%

XOMA Royalty Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XOMA
XOMA Royalty
4.2919 of 5 stars
$27.71
+4.7%
$69.50
+150.8%
+7.3%$316.64M$28.49M-24.1010High Trading Volume
XOMAO
XOMA
N/A$25.18
-0.6%
N/A+1.2%$0.00$13.05M0.0010High Trading Volume
DVAX
Dynavax Technologies
4.3565 of 5 stars
$10.30
+0.3%
$24.00
+133.0%
-5.3%$1.23B$277.25M-19.81350
INVA
Innoviva
4.2829 of 5 stars
$18.91
-1.6%
$55.00
+190.9%
+16.0%$1.21B$358.71M-18.72100Positive News
NVAX
Novavax
4.4629 of 5 stars
$6.61
-2.8%
$17.00
+157.2%
-41.6%$1.10B$682.16M2.491,990
MNKD
MannKind
2.5142 of 5 stars
$3.54
-1.7%
$10.33
+191.9%
-32.8%$1.09B$285.50M35.40400
OPK
OPKO Health
4.5292 of 5 stars
$1.34
-1.5%
$2.75
+105.2%
+5.4%$1.08B$713.10M-19.142,997
GERN
Geron
2.8304 of 5 stars
$1.37
-4.2%
$5.06
+269.5%
-69.3%$910.79M$76.99M-6.5270
RGLS
Regulus Therapeutics
1.5739 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830
MYGN
Myriad Genetics
4.1336 of 5 stars
$5.29
-5.5%
$14.38
+171.9%
-78.0%$516.19M$837.60M-4.722,700
ZBIO
Zenas BioPharma
1.2012 of 5 stars
$9.79
-2.4%
$36.67
+274.5%
N/A$419.60M$5M0.00N/A

Related Companies and Tools


This page (NASDAQ:XOMA) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners